These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 1782089)

  • 41. [Neoadjuvant treatment for locally advanced breast cancer. Comparison of two schemes based on docetaxel-epirubicin vs. 5-fluorouracil-epirubicin-cyclophosphamide].
    Cortés-Flores AO; Morgan-Villela G; Castro-Cervantes JM; Vázquez-Camacho G; Fuentes-Orozco C; González-Ojeda A
    Cir Cir; 2008; 76(1):23-8. PubMed ID: 18492416
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Paclitaxel, epirubicin and cyclophosphamide combination in first-line treatment of metastatic breast cancer: a dose escalation study.
    Bonneterre J; Tubiana-Hulin M; Catimel G
    Oncology; 2004; 66(3):185-91. PubMed ID: 15218308
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Comparison of two multi-drug chemotherapy regimens based on mitoxantrone and epirubicin in 44 patients with non-Hodgkin's lymphoma].
    Gao HR
    Zhonghua Zhong Liu Za Zhi; 1991 Jul; 13(4):287-90. PubMed ID: 1806350
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Chemotherapy of breast cancers. Coordinated evolution of therapeutic schemes from 1975 to 1985].
    Chauvergne J; Durand M; Mauriac L; Hoerni B; David M
    Rev Fr Gynecol Obstet; 1986 Mar; 81(3):119-22. PubMed ID: 3085195
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial.
    Wu W; Deng H; Rao N; You N; Yang Y; Cao M; Liu J
    Trials; 2017 Oct; 18(1):497. PubMed ID: 29070044
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Adjuvant high-dose chemotherapy with epirubicin and ifosfamide in nodal positive breast cancer.
    Lüftner D; Wagner K; Dingeldein G; Haas A; Sezer O; Mergenthaler HG; Wernecke KD; Possinger K
    Anticancer Res; 1999; 19(4C):3583-90. PubMed ID: 10629656
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group.
    Coombes RC; Bliss JM; Wils J; Morvan F; Espié M; Amadori D; Gambrosier P; Richards M; Aapro M; Villar-Grimalt A; McArdle C; Pérez-López FR; Vassilopoulos P; Ferreira EP; Chilvers CE; Coombes G; Woods EM; Marty M
    J Clin Oncol; 1996 Jan; 14(1):35-45. PubMed ID: 8558217
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dose-response relationship of epirubicin-based first-line chemotherapy for advanced breast cancer: a prospective randomized trial.
    Focan C; Andrien JM; Closon MT; Dicato M; Driesschaert P; Focan-Henrard D; Lemaire M; Lobelle JP; Longree L; Ries F
    J Clin Oncol; 1993 Jul; 11(7):1253-63. PubMed ID: 8315422
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Randomized trial of adjuvant chemotherapy for operable breast cancer comparing i.v. CMF to an epirubicin-containing regimen [see comment].
    Mauriac L; Durand M; Chauvergne J; Dilhuydy JM; Bonichon F
    Ann Oncol; 1992 Jun; 3(6):439-43. PubMed ID: 1498061
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The efficacy and safety of preoperative chemotherapy with triweekly abraxane and cyclophosphamide followed by 5-Fluorouracil, epirubicin, and cyclophosphamide therapy for resectable breast cancer: a multicenter clinical trial.
    Shigematsu H; Kadoya T; Masumoto N; Sasada T; Emi A; Ohara M; Kajitani K; Okada M
    Clin Breast Cancer; 2015 Apr; 15(2):110-6. PubMed ID: 25454688
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase I/II trial of adjuvant dose-dense docetaxel/epirubicin/cyclophosphamide (TEC) in stage II and III breast cancer.
    Burdette-Radoux S; Wood ME; Olin JJ; Laughlin RS; Crocker AM; Ashikaga T; Muss HB
    Breast J; 2007; 13(3):274-80. PubMed ID: 17461902
    [TBL] [Abstract][Full Text] [Related]  

  • 52. High pathologic complete response in HER 2-positive locally advanced breast cancer after primary systemic chemotherapy with weekly docetaxel and epirubicin.
    Chen SC; Chang HK; Lin YC; Hsueh S; Cheung YC; Leung WM; Tsai CS; Lo YF; Tsai HP; Shen SC; Chen MF
    Jpn J Clin Oncol; 2008 Feb; 38(2):99-105. PubMed ID: 18270380
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Comparison of epirubicin and cyclophosphamide in 2-dose levels and classical CMF protocol in node-positive breast cancer. An adjuvant Phase III trial].
    Ost E; Illiger HJ
    Strahlenther Onkol; 2002 Jan; 178(1):54-5. PubMed ID: 11977396
    [No Abstract]   [Full Text] [Related]  

  • 54. Epirubicin regimen cuts risk of death in premenopausal women with early breast cancer.
    Oncology (Williston Park); 1999 Dec; 13(12):1740. PubMed ID: 10631703
    [No Abstract]   [Full Text] [Related]  

  • 55. Comparative study of dose escalation versus interval reduction to obtain dose-intensification of epirubicin and cyclophosphamide with granulocyte colony-stimulating factor in advanced breast cancer.
    Lalisang RI; Wils JA; Nortier HW; Burghouts JT; Hupperets PS; Erdkamp FL; Schouten HC; Blijham GH
    J Clin Oncol; 1997 Apr; 15(4):1367-76. PubMed ID: 9193328
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of long term cardiotoxicity after epirubicin containing adjuvant chemotherapy and locoregional radiotherapy for breast cancer using various detection techniques.
    Meinardi MT; Van Der Graaf WT; Gietema JA; Van Den Berg MP; Sleijfer DT; De Vries EG; Haaksma J; Boomsma F; Van Veldhuisen DJ
    Heart; 2002 Jul; 88(1):81-2. PubMed ID: 12067953
    [No Abstract]   [Full Text] [Related]  

  • 57. Phase II trial of high-dose epirubicin and cyclophosphamide in advanced breast cancer.
    Scinto AF; Cercato MC; Botti C; Tonachella R; Ferraresi V; Del Bianco S; Sacchi I; Cognetti F
    Eur J Cancer; 1994; 30A(9):1285-8. PubMed ID: 7999414
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Cancer of the breast in young women: should chemotherapy be intensified?].
    Piccart MJ
    Pathol Biol (Paris); 1992 Nov; 39(9):843-4. PubMed ID: 1371604
    [No Abstract]   [Full Text] [Related]  

  • 59. Docetaxel alternating with epirubicin and cyclophosphamide: a feasibility study in breast cancer patients.
    ten Bokkel Huinink WW; Lustig V; Dubbelman R; Hiemstra A; Rodenhuis S
    Eur J Cancer; 1997 Aug; 33 Suppl 7():S23-5. PubMed ID: 9486100
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: results of a multicenter, randomized phase III study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter Gruppo Group.
    Del Mastro L; Venturini M; Lionetto R; Carnino F; Guarneri D; Gallo L; Contu A; Pronzato P; Vesentini L; Bergaglio M; Comis S; Rosso R
    J Clin Oncol; 2001 Apr; 19(8):2213-21. PubMed ID: 11304774
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.